IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.
--------
54:07
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress
Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.
--------
1:54:49
Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances
Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here.
--------
1:01:12
5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.
--------
13:48
5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. CME information and select publications here.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
Österreich